Genmab — April 2013
-
growth strategy through innovation and other bullshit bingo ways
-
venezuela kostede 4 cents per share
-
devalueringen altså
-
1,44 vs 1,40 (consensus)
-
tjener kassen på linse(r)
-
update på pipeline!
-
invocana først
-
på diabetes
-
ibrutinib
-
breakthrough
-
daratumumab ikke nævnt
-
guidance
-
6 billion of netcash
-
vækst på 5,7-6,7 som er højere end guidance
-
der er lidt opjustering
-
så er der q&a
-
citigruop
-
nice answer på deres afskrivninger
-
de blev spurgt om de vil tage det ud af deres nongaap earnings
-
hvilket vil på virker værdien 6 dollar op
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind